Wave Life Sciences Ltd. Aktie News

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or twice annual dosing

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Wave Life Sciences Ltd. ( WVE ) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics October 29, 2025 10:00 AM EDT Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Christopher Wright - Chief Medical Officer Erik Ingelsson - Chief Scientific Officer Chandra Vargeese - Chief Technology Officer Confere...

This press release corrects and replaces the company's press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under “WVE-007  (GalNAc-siRNA)” – “Next steps.”

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well tolerated to date

CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that it will host a virtual Research Day on Wednesday, October 29, 2025 at 10:00 a.m. ET. In addition, members of Wave's management team are scheduled to participate...

Wave Life Sciences Ltd. (NASDAQ:WVE ) Positive RestorAATion-2 Clinical Data Update Transcript Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Christopher Wright - Chief Medical Officer Erik Ingelsson - Chief Scientific Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Joon Lee - Truist Securities, ...

Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT)